Critical Issues and Recent Advances in Anticoagulant Therapy: A Review

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Aging populations face increased incidence of atrial fibrillation and venous thromboembolism, necessitating effective anticoagulation.
• Traditional anticoagulants (heparin, LMWH, warfarin) have limitations including bleeding risk, administration route, and monitoring requirements.
• Managing thromboembolic diseases is a significant clinical challenge due to high prevalence and severe consequences.

Purpose of the Study:

• To provide an overview of coagulation mechanisms and current anticoagulation therapies.
• To update on the utility and recent advancements of new oral anticoagulants (NOACs).
• To compare NOACs with vitamin K antagonists (VKAs) regarding advantages, disadvantages, precautions, and contraindications.

Main Methods:

• Review of existing literature on coagulation and anticoagulation.
• Analysis of recent studies and clinical trials on NOACs and VKAs.
• Comparative assessment of pharmacological profiles and clinical outcomes.

Main Results:

• NOACs present distinct profiles compared to VKAs, offering potential advantages in specific patient populations.
• Understanding the nomenclature, benefits, drawbacks, and contraindications of NOACs is crucial for clinical application.
• Recent clinical trials provide evidence for the efficacy and safety of NOACs in preventing stroke and thromboembolism.

Conclusions:

• NOACs represent a significant advancement in anticoagulation therapy for atrial fibrillation and venous thromboembolism.
• Careful consideration of patient-specific factors is necessary when selecting between NOACs and VKAs.
• Further research continues to refine the role of NOACs in managing thromboembolic disorders.